Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$14.45 - HK$30.12
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$67.75B
Enterprise ValueHK$39.54K
Total Cash (Recent Filing)HK$2.97B
Total Debt (Recent Filing)HK$7.08B
Price to Earnings (P/E)38.8
Beta1.91
Next Earnings
Aug 31, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield0.98%
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.70
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$29.28Price Target Upside21.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.26
Revenue Forecast (FY)HK$18.76B
Bulls Say, Bears Say
Bulls Say
Profitability / MarginsSustained double-digit EBIT and net margins indicate durable operating leverage in Pharmaron’s service mix. This margin base supports reinvestment in labs and capacity, funds quality hiring, and provides buffer versus project timing swings typical in CRDMO businesses.
Low Leverage / Balance SheetA low debt-to-equity ratio gives Pharmaron financial flexibility to fund capex, expand capacity, or weather client timing variability without resorting to dilutive financing. It strengthens resilience across multi-year contracts and supports strategic investments.
End-to-end CRDMO ModelAn integrated service offering across discovery, development and manufacturing creates cross-sell opportunities and client stickiness. This vertical breadth reduces single-project revenue volatility and positions Pharmaron to capture larger, longer-duration programs.
Bears Say
Weak Cash ConversionSubpar cash conversion and volatile free cash flow constrain the firm’s ability to self-finance growth or return cash to shareholders. Persistent working-capital swings or reinvestment needs could force external financing or delay capacity projects.
Slowing Revenue GrowthA material slowdown in topline expansion reduces operating leverage upside and limits margin recovery potential. For a CRDMO, sustained low growth signals tougher client wins or pricing pressure, making future scale-driven margin improvement more difficult.
Margin Compression / Limited ROE UpsideCompression from prior margin peaks and stagnant ROE suggest structural cost pressure or adverse mix toward lower-margin work. Without clear operating leverage restoration, capital efficiency may remain capped, limiting long-term return expansion.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$14.45 and its highest was HK$30.12 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$67.75B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 41 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.212 earnings per share for the quarter, missing the consensus estimate of HK$0.24 by -HK$0.028.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.23 which represents an annual dividend yield of 0.98%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.29.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.212 in its last earnings report, missing expectations of HK$0.24. Following the earnings report the stock price went up 5.926%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$29.28 (21.27% Upside)
HK$29.28 (21.27% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
0.98%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
3759 Stock 12 Month Forecast
Average Price Target
HK$29.28
▲(21.27% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Frontage Holdings Corp.
―
Viva Biotech Holdings
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―